Molecular Mechanism of αAN101D-Transgene-Induced Age-Related Cataract
αAN101D转基因诱发年龄相关性白内障的分子机制
基本信息
- 批准号:10597653
- 负责人:
- 金额:$ 39.48万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2020
- 资助国家:美国
- 起止时间:2020-04-01 至 2025-03-31
- 项目状态:未结题
- 来源:
- 关键词:ActinsAffectAgingAsparagineAspartic AcidBindingCDC42 geneCataractCrystallinsCytoskeletonDNA Sequence AlterationDefectDepositionDevelopmentDiseaseEpithelial CellsEpitheliumExhibitsGoalsHumanHydrophobicityIn VitroK ATPaseKineticsLens OpacitiesLens developmentLinkLiteratureMass Spectrum AnalysisMembraneModelingModificationMolecularMolecular ChaperonesMusNa(+)-K(+)-Exchanging ATPasePathogenicityPhenotypePlayPost-Translational Protein ProcessingPrecipitationPredispositionPropertyProteinsResolutionRoleStructural ProteinStructureTestingTherapeuticTight JunctionsTransgenesTransgenic MiceWaterWild Type Mouseage relatedagedcell motilitycrosslinkdeamidationfiber cellin vivoinsightlensmigrationmouse modelprotein protein interactionrhorho GTP-Binding Proteins
项目摘要
The proposal has the overall goal to determine the molecular mechanisms of an age-related cortical cataract
development. Cataracts are principally a lens structural proteins' (crystallins) aggregation and subsequent
precipitation disease that are inducible by genetic mutations, and occurs due to aging. During cataract
development, the increased sizes of aggregated and cross-linked crystallin multimers become so large that they
finally become water insoluble and cause lens opacity. Several post-translational modifications (PTMs) of
crystallins are known to cause age-related cataracts, and the deamidation of crystallins (the most abundant
among post-translational modifications) is considered as a major cataract-causative factor. In spite of voluminous
literature on in vitro studies of effects of crystallins' deamidation leading to cataract-development, no clear
molecular mechanism has emerged that could implicate the deamidation-induced link of the in vitro effects to in
vivo changes. Therefore, the PI's-generated unique αA-N101D mouse model, where asparagine 101 is
deamidated to aspartic acid, provides an opportunity to directly link the in vitro studies to in vivo changes in
phenotypic and crystallins' properties to the cortical cataract development. The model would provide information
about the molecular mechanism of age-related cataract development. Based on our extensive results, we have
hypothesized that the cataract in αAN101D mouse model is caused by the altered crystallin properties, cellular
defects and synergistically increased deposit of αAN101D with membrane, resulting in membrane disruption and
ionic imbalance. We plan to test the above hypothesis by seeking answers the following three questions using
the above mouse model: (A) Aim 1: Does deamidated αAN101D causes temporal alterations in crystallin-
crystallin interactions leading to aggregation among crystallins and their insolubilization in vivo? (B)
Aim 2: What are the temporal sequence of lens phenotypes that cause cellular defects during the cortical
cataract development? (C) Aim 3: Does temporal increase in binding of deamidated αAN101D to
membrane leads to membrane disorganization and intracellular ionic imbalance? The results will be of
significant therapeutic value to delay the development and progression of age-related cataracts.
该提案的总体目标是确定年龄相关性皮质性白内障的分子机制
发展白内障主要是透镜结构蛋白(晶体蛋白)聚集和随后的
沉淀性疾病是由基因突变诱导的,并且由于衰老而发生。在白内障
随着晶体蛋白多聚体的发育,聚集和交联的晶体蛋白多聚体的尺寸增加,
最终变成水不溶性并导致透镜不透明。几种翻译后修饰(PTM)
已知晶体蛋白引起年龄相关性白内障,并且晶体蛋白的脱酰胺化(最丰富的
在翻译后修饰中)被认为是白内障的主要致病因素。尽管有大量的
关于晶体蛋白脱酰胺作用导致白内障发展的体外研究的文献,
已经出现的分子机制可能涉及脱酰胺诱导的体外效应与胰岛素抵抗之间的联系。
体内变化。因此,PI生成的独特α A-N101 D小鼠模型,其中天冬酰胺101是
脱酰胺为天冬氨酸,提供了将体外研究与体内变化直接联系起来的机会,
表型和晶体蛋白的性质对皮质性白内障的发展。该模型将提供信息
关于年龄相关性白内障发展的分子机制。根据我们的广泛结果,我们有
假设α AN 101 D小鼠模型中的白内障是由晶状体蛋白性质的改变、细胞凋亡和白内障形成引起的。
缺陷并协同增加α AN 101 D与膜的存款,导致膜破裂,
离子失衡我们计划通过使用以下三个问题寻求答案来测试上述假设
上述小鼠模型:(A)目的1:脱酰胺α AN 101 D是否引起晶状体蛋白-
晶体蛋白相互作用导致晶体蛋白之间的聚集和它们在体内的不溶解?(B)
目的2:在皮质骨发育过程中,导致细胞缺陷的透镜表型的时间顺序是什么?
白内障发展?(C)目的3:脱酰胺α AN 101 D与
膜导致膜解体和细胞内离子失衡?结果将是
对延缓年龄相关性白内障的发展和进展具有显著的治疗价值。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Om Prakash Srivastava其他文献
Childhood neglect: a clinical perspective and introducing the Graded Care Profile 2
- DOI:
10.1016/j.paed.2020.08.003 - 发表时间:
2020-11-01 - 期刊:
- 影响因子:
- 作者:
Om Prakash Srivastava;Dawn Hodson - 通讯作者:
Dawn Hodson
Om Prakash Srivastava的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Om Prakash Srivastava', 18)}}的其他基金
Molecular Mechanism of αAN101D-Transgene-Induced Age-Related Cataract
αAN101D转基因诱发年龄相关性白内障的分子机制
- 批准号:
10376357 - 财政年份:2020
- 资助金额:
$ 39.48万 - 项目类别:
PROTEINASE INHIBITORS & CRYSTALLIN FRAGMENTS IN CATARACT
蛋白酶抑制剂
- 批准号:
6131752 - 财政年份:1993
- 资助金额:
$ 39.48万 - 项目类别:
PROTEINASE INHIBITORS & CRYSTALLIN FRAGMENTS IN CATARACT
蛋白酶抑制剂
- 批准号:
6518358 - 财政年份:1993
- 资助金额:
$ 39.48万 - 项目类别:
Proteinase Inhbitors & Crystallin Fragments in Cataract
蛋白酶抑制剂
- 批准号:
7115412 - 财政年份:1993
- 资助金额:
$ 39.48万 - 项目类别:
Proteinase Inhibitors and Crystallin Fragments in Cataract
白内障中的蛋白酶抑制剂和晶状体蛋白片段
- 批准号:
8370202 - 财政年份:1993
- 资助金额:
$ 39.48万 - 项目类别:
Proteinase Inhbitors & Crystallin Fragments in Cataract
蛋白酶抑制剂
- 批准号:
7399654 - 财政年份:1993
- 资助金额:
$ 39.48万 - 项目类别:
Project title Proteinase Inhibitors & Crystallin Fragments in Cataract
项目名称 蛋白酶抑制剂
- 批准号:
7654940 - 财政年份:1993
- 资助金额:
$ 39.48万 - 项目类别:
相似海外基金
Hormone therapy, age of menopause, previous parity, and APOE genotype affect cognition in aging humans.
激素治疗、绝经年龄、既往产次和 APOE 基因型会影响老年人的认知。
- 批准号:
495182 - 财政年份:2023
- 资助金额:
$ 39.48万 - 项目类别:
Parkinson's disease and aging affect neural activation during continuous gait alterations to the split-belt treadmill: An [18F] FDG PET Study.
帕金森病和衰老会影响分体带跑步机连续步态改变期间的神经激活:[18F] FDG PET 研究。
- 批准号:
400097 - 财政年份:2019
- 资助金额:
$ 39.48万 - 项目类别:
The elucidation of the mechanism by which intestinal epithelial cells affect impaired glucose tolerance during aging
阐明衰老过程中肠上皮细胞影响糖耐量受损的机制
- 批准号:
19K09017 - 财政年份:2019
- 资助金额:
$ 39.48万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Does aging of osteocytes adversely affect bone metabolism?
骨细胞老化会对骨代谢产生不利影响吗?
- 批准号:
18K09531 - 财政年份:2018
- 资助金额:
$ 39.48万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Links between affect, executive function, and prefrontal structure in aging: A longitudinal analysis
衰老过程中情感、执行功能和前额叶结构之间的联系:纵向分析
- 批准号:
9766994 - 财政年份:2018
- 资助金额:
$ 39.48万 - 项目类别:
Affect regulation and Beta Amyloid: Maturational Factors in Aging and Age-Related Pathology
影响调节和 β 淀粉样蛋白:衰老和年龄相关病理学中的成熟因素
- 批准号:
10166936 - 财政年份:2017
- 资助金额:
$ 39.48万 - 项目类别:
Affect regulation and Beta Amyloid: Maturational Factors in Aging and Age-Related Pathology
影响调节和 β 淀粉样蛋白:衰老和年龄相关病理学中的成熟因素
- 批准号:
9320090 - 财政年份:2017
- 资助金额:
$ 39.48万 - 项目类别:
Affect regulation and Beta Amyloid: Maturational Factors in Aging and Age-Related Pathology
影响调节和 β 淀粉样蛋白:衰老和年龄相关病理学中的成熟因素
- 批准号:
9761593 - 财政年份:2017
- 资助金额:
$ 39.48万 - 项目类别:
Experimental Model of Depression in Aging: Insomnia, Inflammation, and Affect Mechanisms
衰老过程中抑郁症的实验模型:失眠、炎症和影响机制
- 批准号:
9925164 - 财政年份:2016
- 资助金额:
$ 39.48万 - 项目类别:
Experimental Model of Depression in Aging: Insomnia, Inflammation, and Affect Mechanisms
衰老过程中抑郁症的实验模型:失眠、炎症和影响机制
- 批准号:
9345997 - 财政年份:2016
- 资助金额:
$ 39.48万 - 项目类别: